Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-015-2448-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The usefulness of barium enema using a water-soluble contrast medium as an emergency examination.
Rev Esp Enferm Dig
January 2025
Gastroenterology, Yokkaichi Municipal Hospital.
Background: Colorectal obstruction is a critical condition requiring prompt diagnosis and intervention. Gastrografin, a water-soluble contrast agent, combines diagnostic and therapeutic benefits, facilitating bowel cleansing and enhancing intestinal motility. This study assessed the safety and effectiveness of Gastrografin enemas in emergency settings.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
University of Minnesota, Twin Cities, Minneapolis, MN, USA.
Background: Alzheimer's disease (AD) pathophysiology is complex. Decrease in CSF soluble Aβ and accumulation of amyloid plaques (by amyloid PET) are two distinct biomarkers of amyloid pathology. However, the pathophysiologic process associated with each biomarker is not clear.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Cleveland Clinic Genomic Medicine Institute, Cleveland, OH, USA.
Background: Alzheimer's disease (AD) is a pathologically heterogeneous disease making it a challenge to develop effective treatments. Emerging evidence suggests that there are pathological differences between women and men with AD. More biomarkers are needed to enhance sex-specific precision medicine in AD.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Acumen Pharmaceuticals, Charlottesville, VA, USA.
Background: Sabirnetug (ACU193) is a humanized monoclonal antibody targeting soluble amyloid beta (Aβ) oligomers, which are early contributors to the pathogenesis of Alzheimer's Disease (AD). An ultrasensitive assay was developed to measure sabirnetug pharmacokinetics (PK) in CSF of individuals with early AD in the Phase 1 study INTERCEPT-AD (NCT04931459).
Method: The immunoassay was developed on the Meso Scale Diagnostics (MSD) S-PLEX with improved sensitivity through TURBO-TAG® technology.
Developing Topics.
Alzheimers Dement
December 2024
Acumen Pharmaceuticals, Charlottesville, VA, USA.
Background: Sabirnetug (ACU193) is a humanized IgG2 antibody targeting soluble, synaptotoxic amyloid β oligomers (AβOs). AβOs accumulate in Alzheimer's disease (AD) and induce pre- and post-synaptic changes, resulting in dendritic spine loss, neuronal degeneration, and release of synaptic proteins into the CSF. Recently, we reported that three administrations of sabirnetug in an early AD population (INTERCEPT-AD Phase 1 study, NCT04931459) significantly lowered CSF levels of the post-synaptic protein neurogranin as well as pTau181.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!